Closing the Gap: A Candid Conversation About Ulcerative Colitis with Dr David T. Rubin

The Potential of Histology in Crohn’s Disease

Neurizons Episode 3: Clinical Trial Insights, Multimodal Interventions, & the Future of Brain Health

The Immunological Interplay Between Obesity and Psoriasis

Battle of the Two Titans - Assessing Lack of Treatment Response in Patients with Atopic Dermatitis

Battle of The Two Titans - The AD Saga: Measuring Eligibility for Systemic Therapy

Battle of the Two Titans – The Saga Continues: Assessing Clinical Severity

Battle of the Two Titans - The Saga Continues: Assessing Subjective Burden in Patients with AD

Neurizons Episode 2- Risk Factors, Family History, and the Importance of Brain Health Conversations

Neurizons Episode 1 – Cognitive Health and the PCP’s Role with Dr. Christian Moher

How is unmet need being addressed for patients with CLL?

Advanced Practice Provider Perspectives: Cardiac toxicities when selecting CLL treatment

How do you support patients diagnosed with CLL?

How do you manage resistance and intolerance to targeted therapies in CLL?

Unmet Needs and Resistance Mechanisms in Patients with HR+, HER2- Metastatic Breast Cancer

Supporting Patients With Breast Cancer in the Clinic: Setting the Patient Up for Success

Identification & Treatment of Patients w/ HR+, HER2- #EarlyBreastCancer at a High Risk of Recurrence

Communicating the Risk of Recurrence for Patients With HR+, HER2- Early Breast Cancer

Understanding the Impact of Heterogeneity on Prognosis in HR+, HER2- Metastatic Breast Cancer

Understanding ESR1 Mutations in HR+, HER2- Metastatic Breast Cancer

What Challenges Have You Encountered with Prognostic Testing in CLL?

What is Your Approach to Prognostic Testing in Patients with CLL?

The Evolving Role of APPs in the Treatment and Management of CLL

Clinical Pharmacist Led Patient Education in Chronic Lymphocytic Leukemia (CLL)

The Role of the Clinical Pharmacist in the Treatment of Chronic Lymphocytic Leukemia (CLL)

How do you see the widespread implementation of rapid NGS improving patient care?

What prompted you to consider internalizing comprehensive genomic profiling?

Is rapid NGS cost-effective?

What would you say to institutions that do not have in-house comprehensive genomic profiling?

How has use of rapid NGS changed patient care at your institution?

What are the advantages of rapid NGS? How has it changed workflows at your hospital system?

Advanced Practice Provider Perspectives: Adverse Event Management for Patients with CLL

Pharmacist Perspectives: Supportive Care for Patients with CLL

What is your approach to supportive care and preventive measures for patients with CLL?

What factors do you consider when treating patients with CLL?

How do you select therapy for patients with CLL?